• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
    • Supply Chain
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

non-small cell lung cancer

Green traffic light
Pharma

FDA signs off on AZ spinout Dizal's lung cancer drug Zegfrovy

Dizal has gained its first FDA approval, winning an accelerated nod for Zegfrovy to become the only oral treatment for those with a rare type of NSCLC.
Kevin Dunleavy Jul 7, 2025 11:28am
Office building showing Daiichi Sankyo logo

FDA signs off on AZ, Daiichi's Datroway for EGFR-mutated NSCLC

Jun 24, 2025 8:10am
Graphic for the Podnosis podcast by Fierce featuring a stylized heart at the center surrounded by colorful sound wave visual

AbbVie, ADCs and the future of cancer care

Jun 20, 2025 9:39am
David Hung Medivation CEO

With lung cancer FDA nod, it's David versus Goliath

Jun 11, 2025 4:17pm
Opdualag

ASCO: Bristol CMO brushes off LAG-3 concern after melanoma flop

Jun 3, 2025 8:00am
sun

Summit shares results from ivonescimab's first global ph. 3 trial

May 30, 2025 9:04am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings